0000000000261275

AUTHOR

William R. Hiatt

showing 8 related works from this author

Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation: The ARAPACIS Study

2017

Abstract Background and aims Vascular disease (VD), as assessed by history of myocardial infarction or peripheral artery disease or aortic plaque, increases stroke risk in atrial fibrillation (AF), and is a component of risk assessment using the CHA 2 DS 2 -VASc score. We investigated if systemic atherosclerosis as detected by ultrasound carotid plaque (CP) could improve the predictive value of the CHA 2 DS 2 -VASc score. Methods We analysed data from the ARAPACIS study, an observational study including 2027 Italian patients with non-valvular AF, in whom CP was detected using Doppler Ultrasonography. Results VD was reported in 351 (17.3%) patients while CP was detected in 16.6% patients. Ad…

Atherosclerosis Atrial fibrillation Carotid plaque CHA2DS2-VASc score Stroke Vascular diseaseCarotid Artery DiseasesMaleAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA2DS2-VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyatrialf fibrillation0302 clinical medicineRetrospective StudieRisk FactorsCarotid artery diseaseAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentAtrial Fibrillation80 and over030212 general & internal medicineMyocardial infarctionStrokeDSAtherosclerosis; Atrial fibrillation; CHA(2)DS(2)-VASc score; Carotid plaque; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentCHA 2 DS 2 -VASc scorePlaqueAtheroscleroticUltrasonographyAged 80 and overIncidenceDopplerAtrial fibrillationCarotid plaquePlaque AtheroscleroticStrokeSurvival RateItalyAtherosclerosiCHA(2)DS(2)-VASc scoreCardiologyartherosclerosis; atrial fibrillation; carotid plaque; CHA2DS2-VASc score; stroke; vascular disease; aged; aged 80 and over; ankle brachial index; atrialf fibrillation; carotid artery diseases; female; humans; incidence; italy; male; plaque atherosclerotic; retrospective studies; risk factors; survival rate; ultrasonography doppler; risk assessment; cardiology and cardiovascular medicineFemaleSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyCHA2DS2-VASc score2Atherosclerosis; Atrial fibrillation; Carotid plaque; CHA 2 DS 2 -VASc score ; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular MedicineSocio-culturaleVascular diseaseRisk Assessment-VASc score03 medical and health sciencesInternal medicinemedicineHumansAnkle Brachial Indexcardiovascular diseasesRisk factorSurvival rateAgedRetrospective StudiesCarotid Artery DiseaseVascular diseasebusiness.industryRisk FactorUltrasonography Dopplermedicine.diseaseAtherosclerosisartherosclerosisCHA2DS2–VASc scoreCHAAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular diseasebusiness
researchProduct

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral …

2017

Abstract Background Patients with peripheral artery disease (PAD) undergoing a lower-extremity revascularization are at heightened risk for ischemic cardiac and limb events. Although intensification of antithrombotic therapy after revascularization has demonstrated benefit in coronary disease populations, this approach has not been well studied or shown consistent benefit in PAD. Recent trial evidence demonstrated that a treatment strategy of rivaroxaban added to background antiplatelet therapy reduced ischemic risk in patients following recent acute coronary syndromes, as well as in patients with stable atherosclerotic vascular disease. Whether these benefits extend to the population of pa…

Malemedicine.medical_specialtymedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialDouble-Blind MethodRivaroxabanlawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctioneducationRivaroxabaneducation.field_of_studyAspirinDose-Response Relationship Drugbusiness.industryEndovascular ProceduresThrombolysisMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeLower ExtremityCardiologyPurinergic P2Y Receptor AntagonistsPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsFollow-Up StudiesAmerican heart journal
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort…

2015

Objective: To investigate the relationship between Ankle-Brachial Index (ABI) and renal function progression in patients with atrial fibrillation (AF). Design: Observational prospective multicentre cohort study. Setting: Atherothrombosis Center of I Clinica Medica of 'Sapienza' University of Rome; Department of Medical and Surgical Sciences of University Magna Græcia of Catanzaro; Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. Participants: 897 AF patients on treatment with vitamin K antagonists. Main outcome measures: The relationship between basal ABI and renal function progression, assessed by the estimated Glomerular Filtration R…

RegistrieMaleAnkle brachial index atrial fibrillation renal functionCross-sectional studyAngiotensin-Converting Enzyme InhibitorsBlood PressureCardiovascular Medicineurologic and male genital diseasesKidneyRisk FactorsAtrial FibrillationOdds RatioSurveys and Questionnaireatrial fibrillation1506Prospective StudiesRenal InsufficiencyPractice Patterns Physicians'Prospective cohort studyMedicine (all)Atrial fibrillationGeneral MedicineMiddle Agedmedicine.anatomical_structureItalyHypertensioncardiovascular systemCardiologyDisease ProgressionFemaleVitamin K antagonistABICohort studyHumanGlomerular Filtration RateAnkle brachial index; atrial fibrillation; renal function1683medicine.medical_specialtyLogistic ModelNon-Vitamin K oral anticoagulantRenal functionrenal function declineAnkle-Brachial IndexNOInternal medicineAged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Cross-Sectional Studies; Disease Progression; Female; Humans; Hypertension; Italy; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Renal Insufficiency; Risk Factors; Ankle Brachial Index; Blood Pressure; Glomerular Filtration Rate; Medicine (all)medicineInternal MedicineHumansAnkle Brachial Indexcardiovascular diseasesIntensive care medicineAgedCross-Sectional StudieAntithrombotic therapybusiness.industryRisk FactorResearchrenal functionAnticoagulantAngiotensin-Converting Enzyme InhibitorOdds ratiomedicine.diseasebody regionsProspective StudieBlood pressureAtrial fibrillation; Ankle-Brachial Index; renal function declineCross-Sectional StudiesLogistic ModelsAnklebusinessABI renal function atrial fibrillation
researchProduct

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization

2021

Abstract Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety and effectiveness in LER for PAD. Methods VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespe…

Rivaroxabanmedicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentThrombolysisRevascularizationPlacebomedicine.diseasechemistry.chemical_compoundPaclitaxelchemistryInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Rivaroxaban in Peripheral Artery Disease after Revascularization

2020

Abstract Background Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and ...

RivaroxabanAspirinmedicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentGeneral MedicineDisease030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trialMulticenter studylawInternal medicineCardiologyMedicine030212 general & internal medicinebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Tri…

2021

Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 mg twice daily plus aspirin or matching placebo plus aspirin and followed …

Lower extremity revascularizationMalemedicine.medical_specialtylower extremity revascularization; major adverse cardiovascular events (MACE); major adverse limb events (MALE); peripheral artery disease; revascularization; rivaroxaban.lower extremity revascularizationArterial diseasemedicine.medical_treatmentDiseaseRevascularizationperipheral artery diseasePeripheral Arterial DiseaseRivaroxabanPhysiology (medical)Internal medicinemedicineHumansIn patientmajor adverse cardiovascular events (MACE)major adverse limb events (MALE)AgedRivaroxabanAspirinAspirinbusiness.industryMiddle AgedCardiologyrevascularizationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugSurgical revascularizationCirculation
researchProduct

Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial

2021

Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb and cardiovascular events. The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial demonstrated that rivaroxaban 2.5 mg twice daily reduced first events by 15%. The benefit of rivaroxaban on total (first and subsequent) events in this population is unknown.This study sought to evaluate the total burden of vascular events in patients with PAD after LER and the efficacy o…

MaleLower extremity revascularizationmedicine.medical_specialtyArterial diseasemedicine.medical_treatmentGlobal HealthRevascularizationPeripheral Arterial DiseaseRivaroxabanIschemiaInternal medicineHumansMedicineAgedRivaroxabanDose-Response Relationship Drugbusiness.industryIncidencefood and beveragesMiddle AgedPeripheralbody regionsTreatment OutcomeLower ExtremityArterial revascularizationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresFactor Xa Inhibitorsmedicine.drugJournal of the American College of Cardiology
researchProduct